Adalimumab News and Research

RSS
Adalimumab is an injectable prescription drug used to treat diseases of the immune system; it is marketed by Abbot as Humira. It is one of three drugs that work by inhibiting the potent inflammatory molecule tumor necrosis factor-alpha (TNF-alpha); the others are etanercept (Enbrel) and infliximab (Remicade). Like etanercept and infliximab, adalimumab is a large protein molecule made with recombinant DNA technology. Adalimumab is a monoclonal antibody of the IgG1 subtype that has been "humanized", meaning that all of its components are derived from human molecules.
People suffering from rheumatoid arthritis with increased disease activity have high thrombosis risk

People suffering from rheumatoid arthritis with increased disease activity have high thrombosis risk

Study focuses on COVID-19 patients with inflammatory rheumatic diseases

Study focuses on COVID-19 patients with inflammatory rheumatic diseases

New study to evaluate drug combination treatment for uveitis

New study to evaluate drug combination treatment for uveitis

Juvenile immune arthritis – new treatments wanted

Juvenile immune arthritis – new treatments wanted

Additional medications needed to control the symptoms of juvenile idiopathic arthritis

Additional medications needed to control the symptoms of juvenile idiopathic arthritis

Study reveals safety, efficacy of live zoster vaccine for people taking TNF inhibitors

Study reveals safety, efficacy of live zoster vaccine for people taking TNF inhibitors

Work in progress on medicine for treatment of ulcerative colitis

Work in progress on medicine for treatment of ulcerative colitis

Study identifies genetic marker which could personalize treatment for Crohn's disease

Study identifies genetic marker which could personalize treatment for Crohn's disease

Common genetic variant explains why immunotherapy often fails in Crohn's disease

Common genetic variant explains why immunotherapy often fails in Crohn's disease

Two uveitis drugs perform similarly in a head-to-head clinical trial

Two uveitis drugs perform similarly in a head-to-head clinical trial

Research suggests new way to improve the efficacy of arthritis drug

Research suggests new way to improve the efficacy of arthritis drug

Still-to-be-approved drug proves to be new option for treating active rheumatoid arthritis

Still-to-be-approved drug proves to be new option for treating active rheumatoid arthritis

Dermcidin in human sweat may contribute to pathogenesis of hidradenitis suppurativa

Dermcidin in human sweat may contribute to pathogenesis of hidradenitis suppurativa

IONTAS founder and pioneer in phage display technology attends Nobel Prize Award Ceremony

IONTAS founder and pioneer in phage display technology attends Nobel Prize Award Ceremony

First biosimilar approved by FDA for treatment of adult patients with non-Hodgkin’s lymphoma

First biosimilar approved by FDA for treatment of adult patients with non-Hodgkin’s lymphoma

Toxic effects of drugs in the lungs 'more widespread than thought'

Toxic effects of drugs in the lungs 'more widespread than thought'

Study offers new hope for people with disabling Dupuytren's disease

Study offers new hope for people with disabling Dupuytren's disease

Study: Psoriasis patients taking Humira show no change in aortic inflammation

Study: Psoriasis patients taking Humira show no change in aortic inflammation

Psoriasis drug also effective at reducing aortic inflammation

Psoriasis drug also effective at reducing aortic inflammation

Finger prick test offers opportunity to simplify therapeutic drug monitoring of biologics

Finger prick test offers opportunity to simplify therapeutic drug monitoring of biologics